In this fascinating episode, explore the cutting-edge world of receptor tyrosine kinase (RTK) therapeutics and their crucial role in fighting cancer. Learn about two major drug categories - tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) - and how they precisely target cancer cells. The episode delves into the challenges of drug resistance and exciting new approaches like bispecific antibodies and antibody-drug conjugates (ADCs). Using the remarkable case study of BCR-ABL inhibitors in treating chronic myeloid leukemia (CML), discover how targeted therapies are transforming fatal diseases into manageable conditions. Perfect for science enthusiasts and anyone interested in the future of cancer treatment.